docid|entityid|type
0|Early Phase Clinical Trial|Topic
0|Peter F. Thall|Author
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper
1|Tianyu Zhan|Author
1|Yiwang Zhou|Author
1|Ziqian Geng|Author
1|Yihua Gu|Author
1|Jian Kang|Author
1|Li Wang|Author
1|Xiaohong Huang|Author
1|Elizabeth H. Slate|Author
2|Pilot Studies Of Structured Treatment Interruptions In Hiv Therapy|Topic
2|Hiv Therapy|Topic
2|Virologic Failure|Topic
2|Novel Hypothesis|Topic
2|Mathematical Model Of Hiv Within-Host Viral Dynamics|Topic
2|Nonlinear Parametric Resonance|Topic
2|Clinical Trial Data|Topic
2|Patient-Specific Resonant Spectra|Topic
2|Immunologic And Virologic Parameters|Topic
2|Romulus Breban|Author
2|Sally Blower|Author
3|Preventive Vaccines|Topic
3|Hiv|Topic
3|Immune Response Markers|Topic
3|Two-Phase Sampling|Topic
3|Txshift R Package|Topic
3|Nima S. Hejazi|Author
3|Mark J. Van Der Laan|Author
3|Holly E. Janes|Author
3|Peter B. Gilbert|Author
3|David C. Benkeser|Author
4|Phase 1-2 Designs|Topic
4|Dose Finding|Topic
4|Clinical Response|Topic
4|Toxicity|Topic
4|Optimal Dose|Topic
4|Generalized Phase 1-2 Design|Topic
4|Candidate Doses|Topic
4|Patients|Topic
4|Long-Term Success Rate|Topic
4|Biological Outcome|Topic
4|Pharmacodynamic Activity|Topic
4|Immunological Effect|Topic
4|Tumor Response|Topic
4|Survival Time|Topic
4|Multivariate Dose-Outcome Models|Topic
4|Bayesian Model Selection|Topic
4|Therapeutically Optimal Dose|Topic
4|Restricted Mean Survival Time|Topic
4|Simulation Study|Topic
4|Cheng-Han Yang|Author
4|Peter F. Thall|Author
4|Ruitao Lin|Author
4|Demo|Paper
5|Randomized Controlled Trials|Topic
5|Intercurrent Events|Topic
5|Immunology Trials|Topic
5|Treatment-Related Intercurrent Events|Topic
5|Treatment-Unrelated Intercurrent Events|Topic
5|Composite Variable Strategy|Topic
5|Hypothetical Strategy|Topic
5|Causal Estimand|Topic
5|Doubly Robust Estimators|Topic
5|Baricitinib|Topic
5|Systemic Lupus Erythematosus|Topic
5|Sizhu Lu|Author
5|Yanyao Yi|Author
5|Yongming Qu|Author
5|Huayu Karen Liu|Author
5|Ting Ye|Author
5|Peng Ding|Author
6|Align|Topic
6|Large Language Models|Topic
6|Anatomical Therapeutic Chemical|Topic
6|Medical Dictionary For Regulatory Activities|Topic
6|Nabeel Seedat|Author
6|Caterina Tozzi|Author
6|Andrea Hita Ardiaca|Author
6|Mihaela Van Der Schaar|Author
6|James Weatherall|Author
6|Adam Taylor|Author
7|Ross M. Kedl|Author
7|Sars-Cov2|Topic
7|Moderna Phase Iii Clinical Trial|Topic
7|Covid-19 Vaccine Trial|Topic
7|Longitudinal Evaluation Of T And B Cell Immunity|Topic
7|An Immunological Autobiography|Paper
8|Sleep Monitoring Algorithm|Topic
8|Hao He|Author
8|Chao Li|Author
8|Wolfgang Ganglberger|Author
8|Kaileigh Gallagher|Author
8|Rumen Hristov|Author
8|Michail Ouroutzoglou|Author
8|Haoqi Sun|Author
8|Jimeng Sun|Author
8|Brandon Westover|Author
8|Dina Katabi|Author
9|Vaccine Efficacy Estimands|Topic
9|Immunological Effects|Topic
9|Behavioral Effects|Topic
9|Mats Stensrud|Author
9|Daniel Nevo|Author
9|Uri Obolski|Author
9|Influenza Vaccine Trial|Topic
9|Belief Variable|Topic
9|Blinding Assessment|Topic
9|Vaccine Trials|Topic
10|Panacea|Topic
10|Trialalign|Topic
10|Trialinstruct|Topic
10|Trialpanorama|Topic
10|Jiacheng Lin|Author
10|Hanwen Xu|Author
10|Zifeng Wang|Author
10|Sheng Wang|Author
10|Jimeng Sun|Author
11|Immune Correlates Of Protection|Topic
11|Correlates Of Risk|Topic
11|Controlled Vaccine Efficacy Curve|Topic
11|Controlled-Risk Curve|Topic
11|50% Neutralizing Antibody Titer|Topic
11|Virologically Confirmed Dengue|Topic
11|Peter B. Gilbert|Author
11|Youyi Fong|Author
11|Marco Carone|Author
11|Cyd14|Paper
11|Cyd15|Paper
12|Rank-Based Identification Of High-Dimensional Surrogate Markers: Application To Vaccinology|Paper
13|Trial2Vec|Topic
13|Zifeng Wang|Author
13|Jimeng Sun|Author
13|Clinical Trials|Topic
13|Umls Knowledge Base|Topic
14|Spot|Topic
14|Zifeng Wang|Author
14|Cao Xiao|Author
14|Jimeng Sun|Author
14|Clinical Trials|Topic
15|Matrix-Valued Time-Series Data Clustering|Topic
15|Low-Dimensional Embedding|Topic
15|Static Clinical Covariates|Topic
15|High-Dimensional Longitudinal Features|Topic
15|Sparse And Irregular Nature Of Sample Collection|Topic
15|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper
15|Immunological Data Set From Patients With Sars-Cov-2 Infection|Topic
15|Intensive Simulations|Topic
16|World Health Organization|Topic
16|Hiv Treatment|Topic
16|Resource-Limited Settings|Topic
16|Clinical And Immunological Markers|Topic
16|Cd4 Cell Counts|Topic
16|Viral Load|Topic
16|Diagnostic Algorithm|Topic
16|Miriam Hospital Immunology Clinic|Topic
16|Tao Liu|Author
16|Joseph W. Hogan|Author
16|Lisa Wang|Author
16|Shangxuan Zhang|Author
16|Rami Kantor|Author
16|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper
17|Clinical Trials|Topic
17|Nlp|Topic
17|Eligibility Classification|Topic
17|Phase 3 Cancer Trials|Topic
17|Non-Cancer Trials|Topic
17|Phase 1 And 2 Cancer Trials|Topic
17|Heart Disease Trials|Topic
17|Type 2 Diabetes Trials|Topic
17|Observational Trials|Topic
17|Yumeng Yang|Author
17|Ashley Gilliam|Author
17|Ethan B Ludmir|Author
17|Kirk Roberts|Author
17|Annotated Eligibility Criteria Dataset|Topic
17|Few-Shot Learning|Topic
17|Cross-Disease Generalization|Topic
18|Trialsynth|Topic
18|Chufan Gao|Author
18|Mandis Beigi|Author
18|Afrah Shafquat|Author
18|Jacob Aptekar|Author
18|Jimeng Sun|Author
19|Natural Language Processing (Nlp) Of Clinical Trial Documents|Topic
19|Ct-Bert|Topic
19|Xiong Liu|Author
19|Greg L. Hersch|Author
19|Iya Khalil|Author
19|Murthy Devarakonda|Author
19|Clinical Trial Nlp|Topic
19|Named Entity Recognition (Ner) Models|Topic
19|Attention-Based Bilstm|Topic
19|Criteria2Query|Topic
20|Ctp-Llm|Topic
20|Phasetransition Dataset|Topic
20|Michael Reinisch|Author
20|Jianfeng He|Author
20|Chenxi Liao|Author
20|Sauleh Ahmad Siddiqui|Author
20|Bei Xiao|Author
20|Clinical Trial Outcome Prediction|Topic
21|Clinical Trial Outcome (Cto) Benchmark|Topic
21|Chufan Gao|Author
21|Jathurshan Pradeepkumar|Author
21|Trisha Das|Author
21|Shivashankar Thati|Author
21|Jimeng Sun|Author
21|Clinical Trials|Topic
21|Drug Discovery And Development|Topic
22|Machine Learning|Topic
22|Clinical Domain|Topic
22|Data Scarcity|Topic
22|Ethical Considerations|Topic
22|Clinical Trials|Topic
22|Privacy Regulations|Topic
22|High Costs|Topic
22|Extended Duration|Topic
22|Large Language Models|Topic
22|Retrieval-Reasoning Few-Shot Framework|Topic
22|Synthetic Clinical Trials|Topic
22|Binary Success/Failure Labels|Topic
22|Clinicaltrials.Gov|Topic
22|Synthetic Data|Topic
22|Real Datasets|Topic
22|Pre-Trained Model|Topic
22|Binary Classifier|Topic
22|Trial Outcome Prediction|Topic
22|Zerui Xu|Author
22|Fang Wu|Author
22|Yuanyuan Zhang|Author
22|Yue Zhao|Author
22|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Paper
23|Clinical Trials|Topic
23|Drug Development|Topic
23|Phase I|Topic
23|Phase Ii|Topic
23|Phase Iii|Topic
23|Phase Iv|Topic
23|Challenges In Clinical Trials|Topic
23|Innovative Technologies|Topic
23|Emerging Therapies|Topic
23|Regulatory Reforms|Topic
23|Global Collaboration|Topic
23|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper
23|Tianyang Wang|Author
23|Ming Liu|Author
23|Benji Peng|Author
23|Xinyuan Song|Author
23|Charles Zhang|Author
23|Xintian Sun|Author
23|Qian Niu|Author
23|Junyu Liu|Author
23|Silin Chen|Author
23|Keyu Chen|Author
23|Ming Li|Author
23|Pohsun Feng|Author
23|Ziqian Bi|Author
23|Yunze Wang|Author
23|Yichao Zhang|Author
23|Cheng Fei|Author
23|Lawrence Kq Yan|Author
24|Bayesian Adaptive Designs|Topic
24|Clinical Trials|Topic
24|Covid-19 Pandemic|Topic
24|Shirin Golchi|Author
24|Efficient Estimation And Uncertainty Quantification|Topic
24|Design Operating Characteristics|Topic
24|Ordinal Disease-Progression Scale Endpoint|Topic
24|Clinical Trial Design|Topic
25|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper
25|Zifeng Wang|Author
25|Chufan Gao|Author
25|Lucas M. Glass|Author
25|Jimeng Sun|Author
25|Clinical Simulation|Topic
25|Individualized Predictive Modeling|Topic
25|Computer-Aided Trial Design|Topic
26|Clinical Trial Outcome Prediction|Topic
26|Language Interaction Network (Lint)|Topic
26|Chufan Gao|Author
26|Tianfan Fu|Author
26|Jimeng Sun|Author
26|Clinical Trials|Topic
26|Biologics|Topic
26|Machine Learning Models|Topic
26|Roc-Auc Scores|Topic
26|Drug Portfolio|Topic
26|Small-Molecule Drugs|Topic
26|Therapeutic Agents|Topic
26|Graph Neural Networks|Topic
26|Free-Text Descriptions|Topic
26|Phases I, Ii, And Iii|Topic
27|Rats|Topic
27|Random Dot Motion Task|Topic
27|Stimulus Integration|Topic
27|Trial Difficulty|Topic
27|Reward-Related Parameters|Topic
27|Pamela Reinagel|Author
27|Emily Mankin|Author
27|Adam Calhoun|Author
28|Bayesian Trial Monitoring Scheme|Topic
28|Latent Gaussian Process (Lgp)|Topic
28|Yanxun Xu|Author
28|Yuan Ji|Author
28|Clinical Trials|Topic
28|Repeated Outcomes|Topic
28|Binary Outcomes|Topic
28|Posterior Inference|Topic
28|Monte Carlo Algorithm|Topic
28|Simulation Studies|Topic
28|Case Study|Topic
28|Real-Life Trial|Topic
28|Trial Monitoring|Topic
28|Futility|Topic
28|Longitudinal Data|Topic
28|Clinical Scenarios|Topic
28|Observed Longitudinal Binary Outcomes|Topic
28|Posterior Consistency Property|Topic
28|Discrete Longitudinal Data|Topic
28|Overall Trial Design|Topic
28|Sample Size|Topic
28|Power Calculation|Topic
29|Clinical Trial Site Matching With Improved Diversity Using Fair Policy Learning|Paper
